Drug Trial Radar · NCT06095583
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
Last checked: Nov 20, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
756
Planned (sponsor's estimate)
Start
Nov 15, 2023
Primary completion
Jul 31, 2027
Study completion Jul 31, 2029
Sponsor
- Lead sponsor
- Shanghai Junshi Bioscience Co., Ltd.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 23, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination with tifcemalimab as consolidation therapy in patients with limited-stage small cell lung cancer without disease progression following chemoradiotherapy. Tifcemalimab is a monoclonal antibody against B and T lymphocyte attenuator (BTLA). Toripalimab is a monoclonal antibody against programmed death protein-1 (PD-1). Neither drug is approved for treatment of This combination regimen is investigational in limited stage-small cell lung cancer in any country.
Conditions
- Limited-stage Small Cell Lung Cancer (LS-SCLC)
Interventions
Tifcemalimab injectionDrug
200mg once every 3weeks
toripalimab injectionDrug
240mg once every 3 weeks
Placebo for TifcemalimabDrug
every 3weeks
Placebo for toripalimabDrug
every 3weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS)Time frame: up to 3years
- OSTime frame: up to 3years
- Progression-free survival (PFS)Time frame: up to 2years
- Progression-free survival (PFS)Time frame: up to 2years
Locations
76 sites in 6 countries. Site status is shown where the registry gives one.
Anyang Tumor Hospital
Anyang, China · Recruiting
Beijing Cancer Hospital
Beijing, China · Not yet recruiting
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, China · Recruiting
Jilin Cancer Hospital
Changchun, China · Recruiting
Hunan Cancer Hospital
Changsha, China · Recruiting
Sichuan cancer hospital
Chengdu, China · Not yet recruiting
Chongqing University Cancer Hospital
Chongqing, China · Recruiting
Peking University Shenzhen Hospital
Guangdong, China · Not yet recruiting
Sun Yat-sen University Cancer Center
Guangzhou, China · Recruiting
No. 1 Bandong Road, Gongshu District, Hangzhou
Hangzhou, China · Recruiting
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, China · Recruiting
The First Affiliated Hospital of Ustc
Hefei, China · Recruiting
Henan Cancer Hospital
Henan, China · Not yet recruiting
Affiliated Hospital of Jining Medical University
Jining, China · Not yet recruiting
The First Affiliated Hospital of Nanchang University
Nanchang, China · Recruiting
The Second Affiliated Hospital of Nanchang University
Nanchang, China · Recruiting
The Affiliated Hospital of Qingdao University
Qingdao, China · Not yet recruiting
Fudan University Shanghai Cancer Center
Shanghai, China · Not yet recruiting
Liaoning cancer hospital
Shenyang, China · Not yet recruiting
Shanxi Cancer hospital
Taiyuan, China · Recruiting
Taizhou Hospital of Zhejiang Province
Taizhou, China · Not yet recruiting
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China · Recruiting
Hubei Cancer Hospital (Hubei Cancer Research Institute)
Wuhan, China · Recruiting
Zhongnan Hospital of Wuhan University
Wuhan, China · Recruiting
The First Affiliated Hospital of Xiamen University
Xiamen, China · Not yet recruiting
General Hospital of Ningxia Medical University
Yinchuan, China · Recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Recruiting
Xiangya Hospital Central South University
Changsha, Hunan, China · Recruiting
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China · Recruiting
The First Hospital of China Medical University
Shenyang, Liaoning, China · Recruiting
Shandong Cancer Hospital & Institute
Jinan, Shandong, China · Recruiting
"TIM - Tbilisi Institute of Medicine" LTD
Tbilisi, Georgia · Not yet recruiting
ICO-Institute of Clinical Oncology - Hospital
Tbilisi, Georgia · Recruiting
LTD "Israel-Georgian Medical Research Clinic Healthycore"
Tbilisi, Georgia · Recruiting
LTD "New Hospitals"
Tbilisi, Georgia · Recruiting
ISR-GEO Med Res Clin Healthycore
Tbilisi, K'alak'i T'bilisi, Georgia · Recruiting
Ltd New Hospitals
Tbilisi, K'alak'i T'bilisi, Georgia · Recruiting
Multprofil Clinic Consilium Medulla
Tbilisi, K'alak'i T'bilisi, Georgia · Recruiting
Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic
Tbilisi, K'alak'i T'bilisi, Georgia · Recruiting
Jeroen Bosch Ziekenhuis
's-Hertogenbosch, Netherlands · Not yet recruiting
Showing 40 of 76 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.